-
公开(公告)号:CA2690483C
公开(公告)日:2012-07-24
申请号:CA2690483
申请日:2002-11-22
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TEGTMEIER FRANK , JANSSENS FRANS EDUARD , LEENAERTS JOSEPH ELISABETH , VAN ROSSEM KOENRAAD ARTHUR , ALCAZAR-VACA MANUEL JESUS , MARTINEZ-JIMENEZ PEDRO , BARTOLOME-NEBREDA JOSE MANUEL , GOMEZ-SANCHEZ ANTONIO , FERNANDEZ-GADEA FRANCISCO JAVIER , VAN REEMPTS JOZEF LEO HENRI
IPC: A61K31/4402 , C07D487/04 , A61K31/138 , A61K31/415 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/445 , A61K31/4535 , A61K31/495 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/5415 , A61K31/55 , A61P1/04 , A61P9/10 , A61P9/12 , A61P29/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07D471/00 , C07D471/04 , C07D487/00 , C07D519/00
Abstract: Disclosed is use of a histamine receptor antagonist for the manufacture of a medicament for reduction of intracranial pressure (ICP). Histamine receptor antagonists useful for this purpose include: histamine H1-receptor antagonists, histamine H2-receptor antagonists and histamine receptor antagonists with a combined H1/H2 antagonistic activity. Also disclosed are uses of the same histamine receptor antagonists for the reduction and prevention of elevated ICP or secondary ischaemia in a mammal, and medicaments for the same.
-
公开(公告)号:CA2467097C
公开(公告)日:2011-02-01
申请号:CA2467097
申请日:2002-11-22
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TEGTMEIER FRANK , JANSSENS FRANS EDUARD , LEENAERTS JOSEPH ELISABETH , VAN ROSSEM KOENRAAD ARTHUR , ALCAZAR-VACA MANUEL JESUS , MARTINEZ-JIMENEZ PEDRO , BARTOLOME-NEBREDA JOSE MANUEL , GOMEZ-SANCHEZ ANTONIO , FERNANDEZ-GADEA FRANCISCO JAVIER , VAN REEMPTS JOZEF LEO HENRI
IPC: A61K31/55 , C07D487/04 , A61K31/415 , A61K31/425 , A61K31/513 , A61K31/517 , A61K31/519 , A61P1/04 , A61P9/10 , A61P29/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07D471/00 , C07D471/04 , C07D487/00 , C07D519/00
Abstract: The invention concerns a novel histamine receptor antagonist and the use of an histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. The novel compounds comprise compounds according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenylmethyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-a]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. Also claimed is the novel use of commercially available histamine H1-and H2-receptor antagonists for the reduction of intracranial pressure (ICP).
-
公开(公告)号:AT423599T
公开(公告)日:2009-03-15
申请号:AT07107669
申请日:2002-11-22
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TEGTMEIER FRANK , JANSSENS FRANS , LEENAERTS JOSEPH , VAN ROSSEM KOENRAAD , ALCAZAR-VACA MANUEL , MARTINEZ-JIMENEZ PEDRO , BARTOLOME-NEBREDA JOSE MANUEL , GOMEZ-SANCHEZ ANTONIO , FERNANDEZ-GADEA FRANCISCO , VAN REEMPTS JOZEF
IPC: A61P9/10 , C07D487/04 , A61K31/415 , A61K31/425 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/55 , A61P1/04 , A61P29/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07D471/00 , C07D471/04 , C07D487/00 , C07D519/00
Abstract: The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular, the histamine antagonist is selected from the group of acrivastine, alimemazine, antazoline, astemizole, azatadine, azelastine, brompheniramine, buclizine, carbinoxamine, carebastine, cetirizine, chlorcyclizine, chlorpheniramine, cinnarizine, clemastine, clemizole, clocinizine, clonidine, cyclizine, cyproheptadine, descarboethoxyloratidine, dexchlorpheniramine, dimenhydrinate, dimethindene, dimethothiazine, diphenhydramine, diphenylpyraline, doxylamine, ebastine, efletirizine, epinastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, loratidine, meclizine, mequitazine, methdilazine, mianserin, mizolastine, niaprazine, noberastine, norastemizole, oxatomide, oxomemazine, phenbenzamine, pheniramine, picumast, promethazine, pyrilamine, temelastine, terfenadine, trimeprazine, tripelennamine, triprolidine, ranitidine, cimetidine, famotidine, nizatidine, tiotidine, zolantidine, ritanserine, and derivatives thereof and mixtures of any two or more of the foregoing.
-
公开(公告)号:NZ550723A
公开(公告)日:2008-06-30
申请号:NZ55072302
申请日:2002-11-22
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TEGTMEIER FRANK , JANSSENS FRANS EDUARD , LEENAERTS JOSEPH ELISABETH , VAN ROSSEM KOENRAAD ARTHUR , ALCAZAR-VACA MANUEL JESUS , GOMEZ-SANCHEZ ANTONIO , FERNANDEZ-GADEA FRANCISCO JAVI , MARTINEZ-JIMENEZ PEDRO , VAN REEMPTS JOZEF LEO HENRI
IPC: C07D487/04 , A61K31/415 , A61K31/425 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/55 , A61P1/04 , A61P9/10 , A61P29/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07D471/00 , C07D471/04 , C07D487/00 , C07D519/00
Abstract: Disclosed is the use of an histamine receptor antagonist for the manufacture of a medicament for the reduction in intracranial pressure (ICP) in a mammal.
-
公开(公告)号:ES2290364T3
公开(公告)日:2008-02-16
申请号:ES02803410
申请日:2002-11-22
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: TEGTMEIER FRANK , JANSSENS FRANS EDUARD , LEENAERTS JOSEPH ELISABETH , VAN ROSSEM KOENRAAD ARTHUR , ALCAZAR-VACA MANUEL JESUS JANS , MARTINEZ-JIMENEZ PEDRO
IPC: C07D487/04 , C07D519/00 , A61K31/415 , A61K31/425 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/55 , A61P1/04 , A61P9/10 , A61P29/00 , A61P37/02 , A61P37/06 , A61P37/08 , C07D471/00 , C07D471/04 , C07D487/00
Abstract: Uso de un compuesto para la fabricación de un medicamento para la inmunomodulación en un mamífero, para la supresión de reacciones de hipersensibilidad y/o inflamatorias y para el tratamiento y la prevención de enfermedades alérgicas y afecciones gastrointestinales, en el que el compuesto es un compuesto según la fórmula general (I) (I) las sales de adición de ácidos o bases farmacéuticamente aceptables del mismo, las formas esteroquímicamente isoméricas del mismo y la forma de N-óxido del mismo, en la que: m es 1 ó 2; n es 0, 1 ó 2; a, b, c son independientemente un enlace sencillo o uno doble; X es un enlace covalente o un radical bivalente de un alcanodiilo C1-6 en el que uno o más grupos -CH2- pueden sustituirse opcionalmente por -O-, -S-, -CO-, o NR7 - en el que: R7 es hidrógeno, alquilo, Ar, Ar-alquilo, Het, Het-alquilo, hidroxialquilo, alquiloxilo, alquiloxialquilo, alquiloxialquiloxialquilo, aminoalquilo, mono o dialquilaminoalquilo, formilo, alquilcarbonilaminoalquilo, alquilcarboniloxialquilo, alquiloxicarbonilo, alquiloxicarbonilalquilo, alquilaminocarbonilo, alquilaminocarbonilalquilo, hidroxialquiloxialquilo, aminocarbonilo, aminocarbonilalquilo, alquiloxicarbonilo o alquilcarboniloxialquiloxialquilo; Y es un radical alcanodiilo C1-4 o alquenodiilo C2-4 bivalente; Z es N, en cuyo caso a es un doble enlace y b es un enlace sencillo o N-R7 en cuyo caso a es un enlace sencillo, b es un enlace doble y R7 se define como anteriormente.
-
公开(公告)号:CA2232195C
公开(公告)日:2006-09-19
申请号:CA2232195
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: MARTINEZ-JIMENEZ PEDRO , ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVI , SIPIDO VICTOR KAREL
IPC: C07D498/14 , A61K31/00 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/553 , A61P1/00 , A61P9/00 , A61P9/12 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D237/30 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D498/22 , C07D513/14 , C07D513/22
Abstract: This invention concerns the compounds of formula (n, the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero to 6; p is zero to 3; q is zero to 3; r is zero to 3; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, trihalomethyl, trihalomethoxy , carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or trihalomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; each formula (i) independently represents a bivalent aromatic heterocycle wherein the heterocycle may be selected from the group consisting of pyrrole pyrrazole, imidazole, triazole, furane, thiophene, isoxazole, oxazole, isothiazole, thiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine; or one of the two bivalent aromatic heterocycles in the compounds of formula (I) may be 1,2-benzenediyl; and aryl is optionally substituted phenyl; it further relates to compositions comprising these compounds, as well as their use as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:CA2448735A1
公开(公告)日:2002-12-19
申请号:CA2448735
申请日:2002-06-11
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: VAN ROSSEM KOENRAAD ARTHUR , ALCAZAR-VACA MANUEL JESUS , FERNANDEZ-GADEA FRANCISCO JAVI , VAN REEMPTS JOS , BARTOLOME-NEBREDA JOSE MANUEL , GOMEZ-SANCHEZ ANTONIO , MARTINEZ-JIMENEZ PEDRO , LEENAERTS JOSEPH ELISABETH , JANSSENS FRANS EDUARD
IPC: A61K9/10 , A61K31/00 , A61K31/519 , A61K31/55 , A61P3/00 , A61P7/10 , A61P9/10 , A61P25/00 , A61P43/00 , C07D471/04 , C07D487/04 , C07D487/14 , C07D495/04 , C07D519/00 , C07D239/00 , C07D277/00
Abstract: The invention concerns novel substituted tetracyclic imidazole derivatives useful for the treatment of elevated intracranial pressure (ICP) and/or secondary ischaemia, in particular caused by brain injury, more in particula r caused by traumatic (TBI) and non-traumatic brain injury, processes for thei r preparation, pharmaceutical compositions comprising them and their use as a medicine. The novel compounds comprise compounds according to the general Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro- 6H - benzimidazo[2,1 -b][3]benzazepin-6-yl) -2-(phenylmethyl)- 1-piperidinyl]ethy l] -2,10-dimethyl pyrimido[1, 2-a]benzimidazol- 4(10H)-one, the pharmaceuticall y acceptable acid or base addition salts thereof, the stereochemically isomeri c forms thereof and the N-oxide form thereof.
-
公开(公告)号:PL326871A1
公开(公告)日:1998-10-26
申请号:PL32687197
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , MARTINEZ-JIMENEZ PEDRO , FERNANDEZ-GADEA FRANCISCO JAVI , SIPIDO VICTOR KAREL
IPC: A61K31/00 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/553 , A61P1/00 , A61P9/00 , A61P9/12 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D237/30 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D498/14 , C07D498/16
Abstract: PCT No. PCT/EP97/01830 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed Apr. 9, 1997 PCT Pub. No. WO97/39001 PCT Pub. Date Oct. 23, 1997This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero to 6; p is zero to 3; q is zero to 3; r is zero to 3; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, trihalomethyl, trihalomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or trihalomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; each independently represents a bivalent aromatic heterocycle wherein the heterocycle may be selected from the group consisting of pyrrole, pyrrazole, imidazole, triazole, furane, thiophene, isoxazole, oxazole, isothiazole, thiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine; or one of the two bivalent aromatic heterocycles in the compounds of formula (I) may be 1,2-benzenediyl; and aryl is optionally substituted phenyl; it further relates to compositions comprising thesae compounds, as well as their use as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:CA2232195A1
公开(公告)日:1997-10-23
申请号:CA2232195
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: SIPIDO VICTOR KAREL , FERNANDEZ-GADEA FRANCISCO JAVI , MARTINEZ-JIMENEZ PEDRO , ANDRES-GIL JOSE IGNACIO
IPC: A61K31/00 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/553 , A61P1/00 , A61P9/00 , A61P9/12 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D237/30 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D498/14 , C07D498/22 , C07D513/14 , C07D513/22
Abstract: This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero to 6; p is zero to 3; q is zero to 3; r is zero to 3; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, trihalomethyl, trihalomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or trihalomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; each formula (i) independently represents a bivalent aromatic heterocycle wherein the heterocycle may be selected from the group consisting of pyrrole, pyrrazole, imidazole, triazole, furane, thiophene, isoxazole, oxazole, isothiazole, thiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine; or one of the two bivalent aromatic heterocycles in the compounds of formula (I) may be 1,2-benzenediyl; and aryl is optionally substituted phenyl; it further relates to compositions comprising these compounds, as well as their use as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
-
-
-
-
-
-
-